The firm reported a 69 percent increase in product sales, driven by a 102 percent jump in cartridge sales and jump in research revenues.
The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.
In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.
Molecular analysis of metastatic CRC in the liver has identified three molecular subtypes that can be coupled with clinical risk scores to inform patient risk.
The team plans to eventually implement the MSI test clinically to determine whether patients are eligible for immunotherapy.
The company plans to submit its 650- to 700-gene panel, which will include microsatellite instability testing, to the FDA for approval as a companion diagnostic.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
The partners will test samples from an NSABP biobank on Nanostring's platform and with standard IHC to look for newer biomarkers of cancer immune evasion.
The researchers plan to add the MSI detection capabilities to an NGS panel and will use the information to guide cancer patients to precision medicine trials.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.